Making Biological Ageing Clocks Personal

3 Murih Pusparum^{1,3}, Olivier Thas^{3,4,5}, Stephan Beck², Gökhan Ertaylan^{1*†}, Simone Ecker^{2*†}

4 ¹Unit Health, Flemish Institute for Technological Research (VITO), Antwerp, Belgium

5 ²UCL Cancer Institute, University College London, London, UK

6 ³Data Science Institute, Hasselt University, Hasselt, Belgium

- 7 ⁴Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium
- 8 ⁵National Institute for Applied Statistics Research Australia (NIASRA), University of Wollongong,
- 9 Wollongong, NSW, Australia.
- 10
- 11 ^{*}Corresponding author
- 12 ⁺Equal Contributions
- 13

14 Summary

15 Background

16 Age is the most important risk factor for the majority of human diseases. Addressing the impact of age-17 related diseases has become a priority in healthcare practice, leading to the exploration of innovative 18 approaches, including the development of predictors to estimate biological age (so-called "ageing 19 clocks"). These predictors offer promising insights into the ageing process and age-related diseases. This 20 study aims to showcase the significance of ageing clocks within a unique, deeply phenotyped 21 longitudinal cohort. By utilising omics-based approaches alongside gold-standard clinical risk predictors, 22 we elucidate the potential of these novel predictors in revolutionising personalised healthcare and 23 better understanding the ageing process.

24 Methods

We analysed data from the IAM Frontier longitudinal study that collected extensive data from 30 healthy individuals over the timespan of 13 months: DNA methylation data, clinical biochemistry, proteomics and metabolomics measurements as well as data from physical health examinations. For each individual, biological age (BA) and health traits predictions were computed from 29 epigenetic clocks, 4 clinical-biochemistry clocks, 2 proteomics clocks, and 3 metabolomics clocks.

30 Findings

Within the BA prediction framework, comprehensive analyses can discover deviations in biological ageing. Our study shows that the within-person BA predictions at different time points are more similar to each other than the between-person predictions at the same time point, indicating that the ageing process is different between individuals but relatively stable within individuals. Individual-based analyses show interesting findings for three study participants, including observed hematological

problems, that further supported and complemented by the current gold standard clinical laboratoryprofiles.

38 Interpretation

39 Our analyses indicate that BA predictions can serve as instruments for explaining many biological

- 40 phenomena and should be considered crucial biomarkers that can complement routine medical tests.
- 41 With omics becoming routinely measured in regular clinical settings, omics-based BA predictions can be
- 42 added to the lab results to give a supplementary outlook assisting decision-making in doctors' 43 assessments.

44 Funding

45 -

46 Keywords:

- 47 Biological age, ageing clock, epigenetic clock, metabolomics clock, proteomics clock, multi-omics,
- 48 personalised health

49 Introduction

50 Age is the most important shared risk factor for the majority of human diseases. Hence, there are strong 51 efforts towards attenuating ageing-related disease risk via lifestyle, pharmacological, and clinical 52 interventions to slow or reverse ageing. "Chronological age" (CA), defined by the time passed since an 53 individual's birth, falls short of reflecting interindividual and environmental differences acting upon a 54 biological system during this period. A critical prerequisite in the endeavour to improve healthy ageing is 55 to quantify an individual's "wellness," which covers not only the absence of sickness but also their 56 resilience to future disease, general satisfaction with their health, and having sufficient energy levels for 57 activities that enrich one's life. While a variety of signals related to individual health and well-being can 58 be collected, validating their contribution to clinically relevant outcomes remains an open issue. The 59 hallmarks of ageing include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, 60 61 cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation 62 and dysbiosis¹. Each hallmark contributes to the ageing process. The major challenge is to dissect the 63 interconnectedness between these hallmarks and their relative contributions to ageing¹.

64 To achieve significant progress in the wellness and longevity area to improve human health span, we 65 need to develop tools and methodologies for standard collection, harmonisation, analysis, integration, and interpretation of this information at the individual level. A variety of biological age predictors have 66 been proposed. They share the common approach of using large cross-sectional "healthy" discovery 67 68 population cohorts with age as a phenotype to construct a predictive model for an organism's age and 69 subsequently validate it in a separate cohort. Based on the type of molecular data employed, these 70 predictors can be classified into six categories: Telomere length, epigenetic clocks, transcriptomic 71 predictors, proteomic predictors, metabolomics-based predictors, and composite biomarker predictors. 72 Among these, epigenetic clocks are considered to be the most accurate in predicting biological age and other health phenotypes². 73

Telomeres are repetitive DNA sequences capping chromosomes that shorten every time a cell divides; thus, telomere length (TL) is a conventional marker of biological ageing across various biological domains.³ TL has been associated with biological age, wellness, and mortality risk of an individual^{4–6}. Furthermore, TL has been proposed for some specific types of cancer⁴ and cardiovascular mortality predictions.^{5,6} However, TL is hard to measure in clinical practice, and recent reports comparing TL with epigenetic clocks on non-symptomatic (or healthy) individuals found TL to be less informative^{2,7–9}.

Epigenetic clocks are molecular tools based on 5mC methylation changes to a person's DNA over time.
 These modifications, which can be influenced by various factors, including environmental exposures and
 lifestyle choices, can change over time and, therefore, be used to predict a person's age.

The "epigenetic clock" premise is to link developmental and maintenance processes to biological ageing, giving rise to a unified theory of the life course of an organism¹⁰. Epigenetic clocks are used in ageing research to identify potential interventions that could delay or reverse age-related changes and to understand the biological processes underlying ageing. They are also employed to study the relationship between epigenetic changes and various age-related diseases and conditions, such as cancer and cardiovascular disease. Epigenetic clocks are not yet widely used in clinical practice but show promise as a way to measure biological ageing and identify interventions that may be able to improve health

90 outcomes. There is a rapidly growing number of epigenetic clock estimators built for distinct 91 purposes^{11,12}, and their application potential, together with the other omics clocks, has also been 92 discussed^{13,14}. Proteomics, metabolomics, and multiple clinical biomarker readouts are used to predict 93 biological age, specific disease risks or phenotypes².

Many of those predictors of age and fitness have already been proposed to be used in healthcare practice, and several companies have started to offer direct-to-consumer products in this context¹⁵. Their product implementation in clinical practice requires rigorous validation and simple and clear recommendations for both the healthcare practitioner and the individual. Hence, despite the large consensus of their premise, there are significant challenges to overcome to transfer scientific health and wellness tools into clinical practice¹⁶.

- 100 In this study, we aim to demonstrate the value of epigenetic clocks, proteomics, metabolomics, and
- 101 multi-biomarker predictors in a unique longitudinal pilot cohort¹⁷ where all required data types (clinical
- 102 parameters, epigenomics, proteomics, metabolomics, along with deep phenotyping and metadata) are
- available across multiple time points in a 13-month period.
- 104

105 Methods

106 Study design and participants

107 The IAM Frontier study is a unique longitudinal cohort study that ran for 13 months in 30 healthy individuals, consisting of 15 male and 15 female participants. The 13 months study duration was chosen 108 109 to cover the seasonal fluctuations that might occur over a one-year period. The study specifically 110 targeted the employees of the research organisation VITO within the age range of 45-59. A major reason 111 for the selection of this group of employees was that as they are part of a research organisation, they 112 are expected to be more open to research-grade technologies and interventions. The age range was 113 selected because the highest prevalence of onset of chronic diseases occurs from the age of 45-65¹⁸. 114 Individuals were selected based on the following inclusion criteria: not suffering from a chronic disease, 115 diagnosed and currently followed-up by a medical specialist: asthma, chronic bronchitis, chronic 116 obstructive pulmonary disease, emphysema, myocardial infarction, coronary heart disease (angina 117 pectoris), other serious heart diseases, stroke (cerebral haemorrhage, cerebral thrombosis), diabetes, 118 cancer (malignant tumour, also including leukaemia and lymphoma). At monthly visits, a range of 119 samples (whole blood, plasma, urine, stool) were collected and sent to accredited laboratories and 120 comprehensive multi-omics and clinical biochemistry data were assessed. Self-administered 121 questionnaires on, for example, health conditions and physical activity were also completed by the 122 participants. In this article, we analysed data from the IAM Frontier study, which included DNA 123 methylation data, clinical biochemistry, proteomics, metabolomics, and data from physical health 124 examinations.

125

126 Sample collection

127 The sampling of the IAM Frontier study took place between March 2019 and March 2020 and included 128 the collection of human biospecimen and digital data. During the 13 months of the study, the

participants donated blood, urine, and stool samples at monthly visits. These samples were collected 129 130 after overnight fasting for at least eight hours. The urine and blood samples (in EDTA-, citrate-, and 131 serum-vacutainers) were transported to the clinical laboratory at room temperature within 6 hours after 132 collection. Peripheral blood mononuclear cells (PBMC) were isolated from EDTA-blood samples, and 133 PBMC pellets were stored at -80°C till the DNA extraction. At monthly visits, clinical tests and health 134 examinations such as blood pressure, body height, weight, and abdominal circumference measurements 135 were performed by accredited labs and appointed doctors. At bi-monthly visits, plasma samples were 136 taken, and omics (proteomics and metabolomics) measurements were assessed. At months one, six, and 137 13, the PBMC samples were used to measure DNA methylation. At month 13, only 20 participants were 138 able to donate samples due to the start of the COVID-19 pandemic. Table 1 presents an overview of the 139 sample collection. All samples have been collected in accordance with the applicable Belgian regulations 140 regarding the use of human body material for scientific research (Belgian Law on use of human body 141 material, 2008) and the Belgian Royal Decree on biobanks (Het Koninklijk Besluit betreffende de biobanken. Belgisch Staatsblad 05.02.2018. Brussels (2018)). 142

Data	Measurement technique	Timepoints – month	Type of sample	Total samples	Remarks
DNA methylation	Illumina Infinium MethylationEPIC BeadChips	2-8-13	РВМС	96	20 samples at month 13, 16 technical replicates
Clinical and physiological	Clinical biochemistry, blood cell counts, health examination	1-2-3-4-5-6-7-8-9- 10-11-12-13	Whole blood, serum PB, fasting urine	380	20 samples at month 13
Metabolomics	NMR - MS	1-3-5-7-9-11-13	Plasma	200	
Proteomics	LC-MSMS -PEA	1-3-5-7-9-11-13	Plasma	200	
Microbiome	Illumina MiSeq	1-6-13	Stool	20	16 samples at month 13

143 **Table 1**: Data collection of IAM Frontier study

144

145

146 **DNA methylation assay**

The DNA methylation assay was carried out using Diagenode Epigenomic Services (Vienna, Austria, Cat No. G02090000). PBMC samples were sent for DNA methylation profiling using the Illumina Infinium MethylationEPIC array BeadChip (850K) platform to analyse the methylation status of more than 850,000 CpGs per sample. This microarray covers 1296% of CpG Islands and 99% of annotated RefSeq genes. We performed the DNA methylation data pre-processing and the corresponding details can be found in Supplementary Document Section 1.

153

154 Analysis of epigenetic clocks and predictors

155 We applied 29 different epigenetic age and health trait predictors (see Figure 2). The Skin & Blood 156 Clock¹⁹, Multi-tissue Clock²⁰, HannumAge²¹, DNAmTL²², PhenoAge²³, GrimAge²⁴, GrimAge DNAmPACKYRS

157 and GrimAge protein levels (DNAmADM, B2M, CystatinC, GDF15, Leptin, PAI1, TIMP1) were obtained by 158 Steve Horvath's DNA Methylation Age Calculator available on http://dnamage.genetics.ucla.edu/. The MethylDetectR predictions (Age, Alcohol, BMI, HDL, BodyFat, Waist:Hip Ratio and Smoking)²⁵ were 159 calculated using the code available at https://zenodo.org/record/4646300. The methylation Pace of Age 160 (mPoA)²⁶ was estimated using the code available at <u>https://github.com/danbelsky/DunedinPoAm38</u>. The 161 MetaClock²⁷ code was received by e-mail from the author Morgan E Levine. EpiTOC scores were 162 calculated using the code available in the corresponding publication.²⁸ EpiTOC2²⁹ scores were calculated 163 using the code available from https://doi.org/10.5281/zenodo.2632938, and MiAge³⁰ scores were 164 165 calculated using the code available from http://www.columbia.edu/~sw2206/softwares.htm. Alcohol predictions³¹ were generated 166 using the dnamlci R package available from https://github.com/yousefi138/dnamalci. Elliot's smoking score³², Zhang's smoking score³³ and 167 EpiSmokEr's smoking status³⁴ were obtained using the R package EpiSmokEr available at 168 169 https://github.com/sailalithabollepalli/EpiSmokEr.

GrimAge, HannumAge, MethylDetectRAge, mPoA, as well as the smoking, alcohol and health trait predictors, were originally developed for whole blood measurements but have been shown to work well with PBMCs in our study and others^{35–38}. Table 2 shows the list of clocks implemented in this study including clocks predicted from clinical, metabolomics, and proteomics data (see the next section).

We also predicted blood counts using minfi³⁹ and the Reinius reference dataset⁴⁰ as well as IDOL using
 the Salas reference dataset⁴¹ with the code available from
 https://github.com/immunomethylomics/FlowSorted.Blood.EPIC.

177 The correlation between predicted and chronological age was calculated using Pearson's correlation.
178 We excluded technical replicates from the calculation of correlation coefficients.

179 For the longitudinal analyses of epigenetic predictions, we used the 16 technical replicates available 180 from our study to estimate technical variation. Two technical replicates were generated within each of the three DNA methylation time points, and ten additional technical replicates of the two previous time 181 182 points were generated at the third time point, providing detailed insight into technical variation 183 influencing the predictions. We used the maximum absolute difference observed between technical 184 replicates as a threshold to define potential biological differences across time points after also adding 185 the chronological time that passed between time points. For example, the maximum absolute differences observed for the Skin & Blood Clock across technical replicates was 2.56 years (the reported 186 median error in blood is 2.5 years¹⁹), and the threshold we used represents the maximum differences 187 188 observed among technical replicates plus the chronological time that passed between the time points 189 which are maximum 343 days (0.94 years).

For the global analyses of our dataset and the identification of biological outliers of interest based on
 our cohort, we introduced a Mean Absolute Deviation (MAD) threshold of +/- 2*MAD and +/- 3*MAD
 across all biological replicates.

- 193
- 194
- 195

Table 2: List of applied clinical and omics ageing clocks. Rows with colours refers to clocks that are

197 further investigated: yellow, red, and blue rows correspond to the clocks that were estimated using

198 clinical, proteomics, and DNA methylation data, respectively.

Clock	Reference	Remarks
MLR-Levine ⁴²	Levine, ME. 2013. Gerontol A Biol Sci	Predicts chronological/biological age
PCA-Levine ⁴²	Med Sci.	Predicts chronological/biological age
KDM	Klemera, P. and Doubal, S. 2006. Mech Ageing Dev. Levine, ME. 2013. Gerontol A Biol Sci Med Sci.	Predicts chronological/biological age
ProtAge-Tanaka ⁴³	Tanaka, T., et al. 2018. Aging Cell.	Predicts chronological/biological age
ProtAge-MD ⁴⁴	Macdonald-Dunlop, E., et al. 2022. Aging.	Predicts chronological/biological age
ClinAge-MD ⁴⁴	Macdonald-Dunlop, E., et al. 2022. Aging.	Overestimated BA (median BA 750 years), not shown
MetaboAge-MD ⁴⁴		Overestimated BA (median BA 600 years), not shown
MetaboAge-vdA ⁴⁵	van den Akker, EB., et al. 2020. Circ Genom Precis Med.	Underestimated BA (median BA –5000 years), not shown
Metabonomics ⁴⁶	Hertel, J., et.al. 2016. Journal of Proteome Research.	Missing variables (only 22% vars. are available), not shown
Skin & blood clock ¹⁹	Horvath, S., et al. 2018. Aging.	Predicts chronological age
MethylDetectR Age ²⁵	Hillary, R. and Marioni, R.	Predicts chronological age
Multi-tissue clock ²⁰	Horvath, S. 2013. Genome Bioloy.	Predicts chronological/biological age
Hannum clock ²¹	Hannum, G., et al. 2013. Molecular Cell.	Predicts chronological/biological age
mPoA ²⁶	Belsky, D., et al. 2020. eLife.	Predicts the pace of ageing
PhenoAge ²³	Levine, M., et al. 2018. Aging.	Predicts health- and lifespan
GrimAge ²⁴	Lu, A., et al. 2019. Aging.	Predicts health- and lifespan
Metaclock ²⁷	Liu, Z., et al. 2020. Aging Cell.	Predicts mortality
EpiTOC ²⁸	Yang, Z., et al. 2016. Genome Biology.	Predicts mitotic age
EpiTOC2 ²⁹	Teschendorff, A.E. 2020. Genome Medicine	Predicts mitotic age
MiAge ³⁰	Youn, A., and Wang, S. 2018. Epigenetics.	Predicts mitotic age
DNAmTL ²²	Lu, A., et al. 2019. Aging.	Predicts telomere length

199

200

201

202 Analysis of Clinical, Metabolomics, and Proteomics Clocks

203 The monthly clinical and bi-monthly metabolomics as well as proteomics data were used for predicting 204 longitudinal biological age using several published calculators. We applied the multiple linear regression (MLR) model and principal component analysis (PCA) developed by Levine et $al.^{42}$ -they will be referred 205 to as MLR-Levine and PCA-Levine—to the clinical data that consist of samples from 12-13 time points per 206 individual. The model prediction involves both clinical and physiological measurements, including total 207 208 cholesterol level, glycated haemoglobin, C-reactive protein, systolic blood pressure, forced expiratory 209 volume (FEV), and cytomegalovirus (CMV). In the IAM Frontier data, FEV and CMV were not measured, but we imputed the values with the corresponding median from the original study⁴⁷. The same clinical 210 variables as in the PCA-Levine model were further used to predict the biological age using the Klemera 211 and Doubal method (KDM).⁴⁸ Unlike the MLR-Levine and the PCA-Levine, KDM also incorporates 212 chronological age in their estimation procedure. Similarly, we also computed other biological age 213 predictions based on similar clinical biochemistry variables developed by McDonald-Dunlop et al.⁴⁴ 214

215 The proteomics and NMR metabolomics data consist of samples from six to seven time points per 216 individual, where the samples were sent to the laboratory in four different batches. For the proteomics data, batch correction normalisation was done prior to the analysis to reduce the technical variation 217 between batches/plates⁴⁹. We performed PCA and multidimensional scaling (MDS) analyses for the 218 metabolomics data, where we did not observe any batch effects, so the raw metabolite abundances 219 220 were used. In both datasets, there are twenty subjects with technical replicates spread across different 221 time points. We performed a procedure for selecting the samples (between the originals and the 222 replicates) by computing cosine similarity coefficients for all samples. The samples with the closest 223 similarity to the rest of the individuals' measurements were selected. Further, we predicted the 224 biological age using other published proteomics and metabolomics clocks: ProtAge-MD (from McDonald-Dunlop et al.¹⁶), MetaboAge-MD, ProtAge-Tanaka, MetaboAge-vdA, and Metabonomics^{43–46}. 225

226 Software tools and programming language

The network (Figure 2) was created in Gephi version 0.9.5⁵⁰ and Cytoscape version 3.8.2⁵¹. All data

analyses were conducted in the R statistical environment version 3.5.1, 4.1.0 and 4.1.3.

229 Results

230 From March 2019 to March 2020, the IAM Frontier study collected monthly samples and data (via online 231 questionnaires and wearable sensors) from 30 healthy (no diagnosed chronic diseases, no self-reported 232 illnesses except hypertension) and highly motivated individuals. An intake interview was performed to 233 check whether the volunteers fit the inclusion and exclusion criteria (health, age, sex balance) and to 234 assess their motivation to join and stay within the study, as the study required monthly site visits for 235 sample collection, continuous wearing of sensors and weekly questionnaires. All individuals were 236 followed up with study doctor visits to inform them about their health status (from the clinical grade 237 biomarkers) as well as provided with genetic counselling with certified personnel when necessary. The 238 study design is illustrated in Figure 1.

In this study, we first explore the global pattern of the values resulting from a multitude of ageing clocks
and examine their utility in predicting personal wellness, health, and biological age (BA). These clocks
were computed for all the IAM Frontier individuals, utilising their clinical biochemistry and physiological

data (such as blood pressure, weight, and height), DNA methylation, metabolomics, and proteomics
measurements. Further, we investigate how these clocks predict outcomes across different time points,
leveraging the longitudinal nature of the IAM Frontier study. Individuals with interesting findings are

subjected to further investigation to demonstrate the importance and the relevance of the omics clocks

- as personal health assistants, capable of monitoring and assisting the clinical examination and diagnosis.
- 247



248

Figure 1: Study design of the IAM Frontier. Longitudinal comprehensive data were collected over the course of the study including monthly physiological and clinical biochemistry data (13 time points), bimonthly proteomics and metabolomics data (7 time points), and six-monthly DNA methylation and microbiome data (3 time points). The study participants consist of 15 males and 15 females, with a (chronological) age range of 45 – 59 years old.

254

255 Figure 2 shows the overview of ageing clocks that can be estimated from various omics measurements. 256 We categorise these clocks according to their utility in predicting 1) BA, 2) blood counts, 3) health traits 257 such as smoking status, alcohol consumption and body mass index (BMI), and 4) plasma protein levels. 258 By using DNA methylation data, 13 clocks aim to predict age, one clock to predict blood counts, 11 259 clocks to predict health traits, and seven clocks to predict plasma protein levels. In addition, three 260 clinical biochemistry clocks, three metabolomics, and two proteomics clocks can also be used for 261 predicting BA from clinical biochemistry data, NMR metabolomics, and Olink proteomics measurements. 262 In this study, we focus on investigating the ageing clocks that are particularly useful in predicting BA.



263

264 Figure 2: The overview of published clinical and omics ageing clocks and predictors discussed in this 265 article. The predictors are grouped based on their purpose on predicting age, blood counts, health traits, 266 and protein levels. Each node represents one predictor connected to another. In the left-hand panel, the 267 edges represent the ratio of shared parameters, e.g., there are 26 shared parameters between the 268 MetaboAge-vdA clock and the MetaboAge-MD clock, hence the thickest edge. The size of each node 269 represents the total number of parameters used in each clock. The right-hand panel shows all DNA 270 methylation predictors used in this study. Edges indicate the parameters used for each predictor. Due to 271 the high numbers of DNA methylation sites used by the predictors, nodes and edges are shown in 272 standard sizes, with no relation to the number of features used or shared.

273

274 In general, in each data type, different ageing clocks use a different set of features. The features used in 275 ageing clocks will further be referred to as variables. Figure 2 shows that there are some variables that 276 are shared and utilised in more than one clock, as demonstrated by the edges between clocks (see MLR-277 Levine and KDM). It is also possible that these variables are shared across different data types, for 278 example between the MLR-Levine and the Metabo-MD where albumin is utilised in both clocks. Albumin 279 and several other variables are present in the clinical biochemistry and metabolomics data; they refer to 280 the same clinical compounds but are measured by different technologies. Since our study focuses on 281 ageing clocks that aim to predict BA, it is also worth noting that there are several omics ageing clocks 282 that include chronological age (CA) in their algorithm, for example, GrimAge and KDM. GrimAge also 283 includes sex and plasma protein levels predicted from the DNA methylation data in its calculation.

Epigenomic, metabolomic and proteomic data are high dimensional. The IAM Frontier study collected the DNA methylation measurements of more than 850,000 sites per sample using Illumina's Infinium MethylationEPIC BeadChips as well as 1,068 proteins and 249 metabolites were measured in the metabolomics and proteomics data of IAM Frontier, respectively. Large numbers of variables are used in

ageing clocks working with these data types. Although several epigenetic age clocks based on only a few loci have been proposed^{26,52}, they tend to be less accurate. The most widely used epigenetic clocks and predictors incorporate between 71²¹ and 1030 CpGs²⁴. In comparison, ageing clocks based on clinical biochemistry data or other omics data (metabolomics, proteomics) require nine to 203 parameters^{42,44}.

292 The clocks we implemented are presented in Table 2. Some of the clocks were not further investigated 293 due to showing unrealistic predictions, unavailable model coefficients (e.g., the model intercept coefficients are not published in the MetaboAge-MD clock), or unavailable variables (e.g., due to 294 differences in the omics technology, around 80% of the required metabolites used in the Metabonomics 295 clock were not measured in the IAM Frontier dataset)^{22,26-30,44-46}. Different sets of variables with 296 297 different sizes are involved in each clock. The included algorithms do not constitute an exhaustive list 298 but were selected in their applicability to the IAM Frontier study with high confidence due to data 299 availability and matching underlying assumptions.

300 Although the study's main objective is focused on BA prediction, CA is still incorporated in some 301 analyses. While CA may not provide the most robust description of human ageing, it offers the most convenient way to calculate age and is perceived as a standard measure of ageing. Stratification by CA 302 group is also often done, for example in clinical reference intervals^{53,54}. For this reason, we believe it is 303 valid to compare the predictions of BA with the subjects' CA; see the Pearson correlation coefficients in 304 305 Table 3. All the clocks shown in Table 3 are significantly correlated with CA; MethylDetectR and the Skin 306 & Blood clock give the highest correlation coefficients, R=0.90 and R=0.87, respectively. This is not 307 unexpected, as both clocks were developed to predict CA. The kernel densities of the predicted BA as 308 well as CA are shown in Figure 3. The predicted Skin & Blood clock age gives a similar kernel density as 309 the CA, both in the position as well as the shape. From this perspective, we may suggest this clock as 310 the best tool to measure individuals' chronological ageing. However, the correlation between 311 chronological age and predicted age among all measured biological clocks is the highest for 312 MethylDetectRAge, another chronological age predictor (Pearson's R=0.91), although its predictions 313 appear to be slightly shifted towards older ages in our dataset. GrimAge, with R=0.85, gives a position 314 of the kernel similar to the chronological age, but with a different shape. GrimAge aims to predict 315 lifespan and healthspan, and as a remark, it also incorporates chronological age in its calculation, unlike 316 the other clocks which are solely based on DNA methylation markers, other omics, or clinical 317 measurements. The same remark also applies to KDM-Levine clock, with R=0.76 and an identical 318 position of the kernel density as compared to the chronological age.

319 We performed different data exploration approaches to compare the BA predictions of each individual 320 who participated in the IAM Frontier study. At each BA predictor, we observed smaller within-person 321 predictions at different time points (focusing on inter-individual variability) than the between-person 322 predictions at the same time point (focusing on intra-individual variability). The small inter-individual 323 variabilities essentially show that the predictions within individuals are closer to each other than 324 between the peers; this observation is similar to the characteristics of common clinical biomarkers when 325 they are measured longitudinally. Therefore, it is reasonable to analyse the results by looking at the 326 differences between individuals, and further explore the fluctuation of the predictions within each 327 individual separately. In Figure 4A, for example, age accelerations which correspond to the difference 328 between predicted BA and CA are shown at time points two, eight, and 13; the time points that are 329 shared between all omics and clinical data. Fairly distinct predictions are observed for each clock, and 330 fluctuations are also seen between time points. Within the same clock, we observe that the between-

- individual fluctuations are larger than the within-individuals'. The age acceleration predictions of
- GrimAge, the Skin & Blood clock, KDM-Levine, PCA-Levine, and ProtAge-Tanaka are close to zero, i.e.
- their predicted BA values are close to the corresponding CAs. Referring to the estimated kernel density
- in Figure 3, the predicted values of these clocks are similar to the CA with reference to the location. The
- predictions observed in the clinical and proteomics data for all time points are shown in Figure 4B.
- 336 **Table 3: Correlation between predicted age and chronological age.** Significant correlations are
- displayed in bold (at p<0.05). *GrimAge and KDM incorporate chronological age in their calculation.

Predictor	Corr. coefficent	p-value
MethylDetectRAge	0.90	2.0E-30
Skin & blood clock	0.87	3.5E-26
GrimAge	0.85	1.1E-23
Multi-tissue clock	0.81	1.6E-19
KDM	0.76	2.2E-16
ProtAge-MD	0.67	2.2E-16
PhenoAge	0.66	3.8E-11
Hannum clock	0.65	4.8E-11
ProtAge-Tanaka	0.60	2.2E-16
MetaClock	0.56	8.7E-08
PCA-Levine	0.48	2.2E-16
MLR-Levine	0.40	1.4E-15
ClinAge-MD	0.37	1.2E-13
ЕріТОС	0.25	2.4E-02
MiAge	0.20	7.6E-02
MetaboAge-vdA	0.18	8.6E-03
mPoA	0.18	1.1E-01
MetaboAge-MD	0.08	2.6E-01
EpiTOC2	0.04	7.4E-01

338

339 We continue the analyses by investigating the BA and health traits predictions in all IAM Frontier 340 participants. Due to the small sample nature of the IAM Frontier study, we are able to examine the 341 individual predictions resulting from all clocks. Figure 5A shows the ordered heatmaps of the predicted 342 BAs as well as the health trait predictions in all individuals at time points two, eight, and 13. These were 343 selected because the results of all clocks are available at these time points, see Table 1. In Figure 5B, the 344 MAD thresholds were computed and were used to give the colour annotations. Therefore, only 345 deviating predictions appear coloured in the figure. We can observe distinct patterns for ID06, ID08 and 346 ID27, detailed below. In Figure 6B, we show the clinical laboratory profiles of these individuals.

ID06 shows very high smoking predictions. ID06 is a current smoker, indeed, and hence has a higher risk of developing cardiovascular diseases (CVD) and diabetes (Supplementary Figure 3 of CVD and diabetes disease risk scores). From the individual plots in Figure 6A, we also observe that the BA predictions of ID06 increase over time for some of the ageing clocks, such as in the Skin & Blood clock and PhenoAge. This individual was also biologically older at all time points according to the KDM and ProtAge-Tanaka clocks. However, the clinical laboratory profiles of ID06 show an increasing trend of the lipid

measurements, in line with this individual's increased risk of CVD and diabetes. Interestingly, ID06's Bcell percentages are higher than the normal range, and the CD4 T-cell and lymphocyte counts are low. This could show that this individual might also have problems with antibodies and the immune system. In the questionnaires, ID06 did not report major health burdens except that this individual felt having low energy, tense muscles, and constant fatigue, with the latter two commonly reported among the study participants.



359

360



363

364 ID08 appears as the only individual with predicted shortened telomeres across both measured time 365 points based on the DNAmTL clock, as seen in Figure 5B. This result may indicate premature ageing. In addition, in almost all the applied epigenetic clocks, this individual was also predicted to be 366 367 epigenetically older at the second time point compared to the first (see Figure 6A). The lipid 368 (cholesterol) profiles of ID08 (see Figure 6B) show an alarming status; the measurements are out-of-369 normal range at almost all time points. Other clinical parameters are still within the normal limits, 370 although the percentages of CD8 T-cell and lymphocyte are high compared to the peers. Based on the 371 weekly questionnaires, during the course of this study, this individual experienced constant fatigue, 372 diarrhoea, numbness, indigestion, sleeping problems, stuffy nose, and blurry vision, see Supplementary 373 Figure 5. Although ID08 does not appear to report all of these health burdens at a significantly higher 374 level than the other study participants, together with the rapid epigenetic ageing and high lipid profiles

observed, they might provide additional support to the premature ageing condition predicted by theDNAmTL clock.

377 ID27 appears to be different in our analyses in many ways, although most of the epigenetic, proteomic 378 and clinical ageing clocks predict this individual to be in a healthy state – healthier and biologically 379 younger than the peers. However, ID27 shows very strong outlier BA predictions corresponding to the 380 Hannum clock as well as very different smoking and health trait predictions. It is the only subject with a 381 completely distinct Hannum age acceleration compared to the peers at all time points, epigenetically 382 younger at the second time point as compared to the first across all clocks, and with conflicting smoking 383 predictions (this individual was not a current smoker). The BA predictions of the clinical and proteomics 384 clocks also show a general decreasing trend over time, where ID27 was biologically younger than 385 chronologically, according to some of those clocks. In addition, from the DNA methylation and 386 proteomics analyses, this subject is discovered to be far outside the main cluster in the corresponding 387 PCA plots (Supplementary Figure 4a and 4b). When looking at DNA methylation predicted blood cell 388 composition, we observe a strongly increased proportion of B cell (Supplementary Figure 6). The finding 389 is confirmed by actual blood counts showing the same abnormalities, clearly indicating a hematological 390 problem. This explains why ID27's age predictions appear as extreme outliers according to Hannum's 391 clock, as it is sensitive to blood composition changes, and may also explain the conflicting and 392 unexpected outlier predictions obtained for several health traits such as smoking and alcohol intake, 393 among others. Throughout the study period, ID27 reported constant medium backpain, a slight 394 headache and blurry vision.



395

Figure 4: Age acceleration of all IAM Frontier participants in different clocks. (A) Age acceleration based
 on the Multi-tissue clock (pink), Skin & Blood clock (yellow), PhenoAge (green), GrimAge (orange),
 MethylDetectR (light blue), and Hannum clock (black). (B) Age acceleration based on MLR-Levine clock

(brown), PCA-Levine clock (light pink), and KDM clock (blue). (C) Age acceleration based on ProtAge Tanaka (grey) and ProtAge-MD (tosca).

401 As the final analysis, we present an unsupervised heatmap and clustering of all predictions and actual measurements of our study in Figure 7. This analysis shows potential patterns arising when all clocks 402 403 and measurements are included and how they may be related to each other. For example, predictions 404 from epigenetic clocks with high Pearson correlation coefficients with CA (MethylDetectRAge, Skin & blood clock, GrimAge) are indeed clustered together with CA, showing a strong linear relationship and 405 406 possibly similar predictive mechanism. However, clinical, proteomics, and metabolomics-based clocks 407 stand apart from this cluster, suggesting their predictive mechanisms may be distinct despite their 408 significant correlations with CA.

409 Also in Figure 7, ID06 and ID27 are clearly seen to be different in several indicators, especially in the 410 blood cells prediction. Our results for ID06, ID08, and ID27 as described above illustrate that the 411 deviation of human biological ageing can be discovered when a comprehensive analysis within the biological age prediction framework is done. The IAM Frontier study followed a communication strategy 412 to discuss these findings, or so-called incidental findings (IF) including genetic alterations back to the 413 IAM Frontier participants⁵⁵. Different clocks can show various results, and additional analyses on further 414 assessment types, such as clinical laboratory tests and reports on personal health problems, can 415 416 complement and enhance the acquired insight.



417

418 **Figure 5: a)** Ordered heatmap. ID06 has higher predicted smoking scores and ID27 is an outlier in several

419 predictions. A slight sex effect is also visible. **b)** Reduced ordered heatmap based on MAD thresholds.



420

Figure 6: a) Age acceleration of ID06, ID08, and ID27. Prediction values that are significantly different
 from the rest of the cohort are marked with full circles. b) Clinical and blood cell profiles of ID06, ID08,

423 and ID27. Measurements that are outside the cohort reference intervals are marked with full circles. The424 blood cell counts are shown in percentages.



Figure 7: Unsupervised heatmap of the estimates of all clocks and predictors together with the actual
measurements. All participants in three DNA methylation time points are included. The clustering based
on the Manhattan-Ward D distances is also showed, annotated by participants' age and sex.

429 Discussion and conclusion

430 Age stands as the principal risk determinant for ailments, impairments and diseases. The pursuit of 431 mitigating age-related illnesses and extending the healthful years of life has led to the innovative idea of 432 directly targeting the ageing process to restore physiological functionality. Realising this ambitious goal 433 necessitates the precise assessment of biological age and the pace of ageing at the molecular level. 434 Propelled by the latest breakthroughs in high-throughput omics technologies, a novel suite of tools has 435 emerged for the quantitative analysis of biological ageing. By leveraging data from various domains such 436 as epigenomics, proteomics, and metabolomics, and employing machine learning techniques, "biological 437 ageing clocks" have been constructed. These clocks have proven their ability to pinpoint potential 438 biomarkers of biological ageing, offering unprecedented insights into the ageing process.

A recent review paints today's landscape of biological age (BA) prediction algorithms using omics 439 technologies⁵⁶. These methods were claimed to better represent the biological state of an organism 440 than the chronological age (CA). Ageing clocks for BA are also starting to appear as commercial products, 441 442 serving as a window into the personal health status. In this manuscript, we use a unique deep-443 phenotyping dataset that allows us to perform and analyse multiple BA predictors using different data 444 types side by side. The longitudinal nature of the data enables us to study the individuals' fluctuations 445 between time points, exploring their changes in BA predictions over time. We optimise our analyses using the extensive set of technical replicates (see Table 1) generated to estimate technical variation in 446 447 our dataset and design our analyses correspondingly (see Methods and Supplementary Material Section 448 1).

449 The BA analyses in the IAM Frontier data shows that BA predictions can fluctuate over time; both an 450 increase and a decrease might happen depending on the biological conditions rather than monotonically 451 increase by time, as in CA. Repeated measurements over time are highly valuable, as outliers can also be 452 caused by normal biological fluctuations. In our study, most BA predictions seem to be "stable", that is, 453 within the expected range of variability across the available time points. However, there are individuals 454 whose predictions do change more than expected over time, and where this is the case, they are often 455 consistent across multiple BA predictors and time points. A comprehensive exploration of the BA 456 prediction differences between individuals of our study leads to three individuals with distinct BA 457 predictions as compared to their peers.

The BA predictions of ID06, ID08 and ID27, give a good example where information from different data types can not only support the results of standard laboratory tests but also provide additional insight. For example, the lipid laboratory test of ID08 shows a worrying result where almost all measurements fall outside the normal ranges. By applying different BA predictors, we discovered that this individual is also predicted to have significantly shortened telomeres across all time points, an indicator of potentially accelerated ageing.

Another important finding is that despite not reporting major or more severe symptoms than the peers,
 ID27 shows strongly altered epigenetic predictions which are reflected in blood cell count abnormalities
 observed in all antibody-related blood cells. These strong alterations may be what impacted some of the

reported epigenetic health trait predictions. Of note, according to the developers of those health trait predictors, they should currently only be used at a population level and are not yet supposed to provide reliable predictions at the individual level. Training data from larger-scale cohorts, including diseased individuals, will be required to refine these additional health trait predictors and enable their clinical use²⁵. Irrespectively, the clearly abnormal epigenetic measurements and predictions of ID27 would undoubtedly also have led to further clinical tests if detected in a wellness- or preventative healthcare setting, revealing the ongoing but previously undetected pathological process.

474 Taken together, our findings demonstrate the value and potential of epigenetic predictors and biological 475 age estimators, particularly for risk assessment and early detection. They can reveal unexpected 476 deviations and inform about the probability of having or developing a disease, for example, as shown 477 here with individual ID27. They can also contribute to known clinically relevant outcomes and serve as 478 vital instruments for explaining many biological phenomena. Currently, the extensive and complex 479 preprocessing procedures required to obtain high quality results from omics data are still hindering 480 many of the corresponding predictors from developing their full clinical potential, in particular at the 481 individual level. However, with the field growing and maturing, we argue that BA predictions should be 482 considered as crucial biomarkers that can well-complement routine medical tests and CA.

Indeed, omics data have already begun to enter clinical practice⁵⁷, making omics-based BA predictions 483 484 feasible. Added to standard laboratory results, they can give a valuable complementary outlook assisting 485 the doctors' decision-making. Once omics technologies have been fully incorporated into the medical 486 routine, BA predictions will likely become standard measurements regularly discussed between patients 487 and medical professionals. A novel personalised value to identify the "normal" BA for an individual could 488 also be estimated, together with common clinical measures, to provide precise individual interpretations^{58,59}. Further longitudinal studies with a more diverse population, including diseased 489 490 patients, will undoubtedly give broader assurance and validation of the significance of BA predictions at 491 the personal level.

492 As the field of biological ageing advances, the construction of BA using ageing clocks employing diverse 493 data sources such as epigenomics, proteomics, and metabolomics could be proven effective in uncovering novel biomarkers of biological ageing. The contemporary trend of profiling cohorts through 494 495 multi-omics technologies is paving the way for a more comprehensive understanding of the molecular 496 underpinnings of ageing. Future endeavours to weave multi-omics into ageing clocks are poised to not 497 only broaden our grasp of the molecular signatures that characterise ageing but also enhance the 498 predictive powers of these models. Furthermore, the successful incorporation of physiological and tissue 499 function parameters into ageing clock models could open new avenues of exploration. The continued 500 expansion of this integrative approach is anticipated to provide more discernible and actionable insights, 501 solidifying the role of ageing clocks as indispensable tools in the evolving landscape of personalised 502 medicine and ageing research.

503 **Contributors**

504 Conceptualisation, M.P., G.E., and S.E.; Formal analysis, M.P. and S.E.; Visualisation, M.P. and S.E.;

- 505 Writing Original draft, M.P., G.E. and S.E.; Writing Review & Editing, G.E. and S.E.; Supervision; G.E.,
- 506 S.E., O.T., and S.B.
- 507 Acknowledgments

508	-
509	
510	
511	Data sharing
512 513	The IAM Frontier longitudinal dataset are available from the corresponding authors on a reasonable request.
514	Declaration of interests
515	No conflicts of interest to disclose.
516	Supplementary Material
517	A supplementary document is available online.
518	References
519 520	 López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. Cell. 2013;153(6):1194-1217. doi:10.1016/J.CELL.2013.05.039
521 522	 Jylhävä J, Pedersen NL, Hägg S. Biological Age Predictors. EBioMedicine. 2017;21:29-36. doi:10.1016/J.EBIOM.2017.03.046
523 524 525	 Blackburn EH, Greider CW, Szostak JW. Telomeres and Telomerase: The Path from Maize, Tetrahymena and Yeast to Human Cancer and Aging.; 2006. http://www.nature.com/naturemedicine
526 527	4. Zhu X, Han W, Xue W, et al. The association between telomere length and cancer risk in population studies OPEN. Published online 2016. doi:10.1038/srep22243
528 529	5. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta- analysis. doi:10.1136/bmj.g4227
530 531 532	 Madrid AS, Rode L, Nordestgaard BG, Bojesen SE. Short Telomere Length and Ischemic Heart Disease: Observational and Genetic Studies in 290 022 Individuals. Published online 2016. doi:10.1373/clinchem.2016.258566
533 534 535	 Breitling LP, Saum KU, Perna L, Schöttker B, Holleczek B, Brenner H. Frailty is associated with the epigenetic clock but not with telomere length in a German cohort. <i>Clin Epigenetics</i>. 2016;8(1):21. doi:10.1186/s13148-016-0186-5
536 537 538 539	 Vetter VM, Meyer A, Karbasiyan M, Steinhagen-Thiessen E, Hopfenmüller W, Demuth I. Epigenetic Clock and Relative Telomere Length Represent Largely Different Aspects of Aging in the Berlin Aging Study II (BASE-II). <i>The Journals of Gerontology: Series A</i>. 2019;74(1):27-32. doi:10.1093/gerona/gly184

540 541 542	9.	Marioni RE, Harris SE, Shah S, et al. The epigenetic clock and telomere length are independently associated with chronological age and mortality. <i>Int J Epidemiol</i> . 2018;47(1):356-356. doi:10.1093/ije/dyx233
543 544	10	. Bocklandt S, Lin W, Sehl ME, et al. Epigenetic Predictor of Age. <i>PLoS One</i> . 2011;6(6):e14821. doi:10.1371/journal.pone.0014821
545 546	11	. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Published online 2018. doi:10.1038/s41576-018-0004-3
547 548	12	. Ecker S, Beck S. The epigenetic clock: a molecular crystal ball for human aging? Aging. 2019;11(2):833-835. doi:10.18632/aging.101712
549 550	13	. Jansen R, Han LK, Verhoeven JE, et al. An integrative study of five biological clocks in somatic and mental health. <i>Elife</i> . 2021;10. doi:10.7554/eLife.59479
551 552 553 554	14	. Crimmins EM, Thyagarajan B, Levine ME, Weir DR, Faul J. Associations of Age, Sex, Race/Ethnicity, and Education With 13 Epigenetic Clocks in a Nationally Representative U.S. Sample: The Health and Retirement Study. <i>The Journals of Gerontology: Series A</i> . 2021;76(6):1117-1123. doi:10.1093/gerona/glab016
555 556 557	15	. Knoppers T, Beauchamp E, Dewar K, et al. The omics of our lives: practices and policies of direct-to-consumer epigenetic and microbiomic testing companies. <i>New Genet Soc</i> . 2021;40(4):541-569. doi:10.1080/14636778.2021.1997576
558 559	16	. Carbonara K, MacNeil AJ, O'Leary DD, Coorssen JR. Profit versus Quality: The Enigma of Scientific Wellness. <i>J Pers Med</i> . 2022;12(1):34. doi:10.3390/jpm12010034
560 561	17	. VITO Health Belgium. I AM Frontier Study. Accessed January 12, 2023. https://iammyhealth.eu/en/i-am-frontier
562 563	18	. MacNee W, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. <i>European Respiratory Journal</i> . 2014;44(5):1332-1352. doi:10.1183/09031936.00134014
564 565 566	19	. Horvath S, Oshima J, Martin GM, et al. Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and ex vivo studies. <i>Aging</i> . 2018;10(7):1758-1775. doi:10.18632/aging.101508
567 568	20	. Horvath S. DNA methylation age of human tissues and cell types. <i>Genome Biol.</i> 2013;14(10):R115. doi:10.1186/gb-2013-14-10-r115
569 570	21	. Hannum G, Guinney J, Zhao L, et al. Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. <i>Mol Cell</i> . 2013;49(2):359-367. doi:10.1016/j.molcel.2012.10.016
571 572	22	. Lu AT, Seeboth A, Tsai PC, et al. DNA methylation-based estimator of telomere length. <i>Aging</i> . 2019;11(16):5895-5923. doi:10.18632/aging.102173
573 574	23	. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10(4):573-591. doi:10.18632/aging.101414

575 576	24. Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. <i>Aging</i> . 2019;11(2):303-327. doi:10.18632/aging.101684
577	25. Hillary RF, Marioni RE. MethylDetectR: a software for methylation-based health profiling.
578	Wellcome Open Res. 2021;5:283. doi:10.12688/wellcomeopenres.16458.2
579 580 581	26. Belsky DW, Caspi A, Arseneault L, et al. Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm. <i>Elife.</i> 2020;9. doi:10.7554/eLife.54870
582 583	27. Liu Z, Leung D, Thrush K, et al. Underlying features of epigenetic aging clocks in vivo and in vitro. <i>Aging Cell</i> . 2020;19(10). doi:10.1111/acel.13229
584	28. Yang Z, Wong A, Kuh D, et al. Correlation of an epigenetic mitotic clock with cancer risk.
585	Genome Biol. 2016;17(1):205. doi:10.1186/s13059-016-1064-3
586	29. Teschendorff AE. A comparison of epigenetic mitotic-like clocks for cancer risk prediction.
587	Genome Med. 2020;12(1):56. doi:10.1186/s13073-020-00752-3
588 589	30. Youn A, Wang S. The MiAge Calculator: a DNA methylation-based mitotic age calculator of human tissue types. <i>Epigenetics</i> . 2018;13(2):192-206. doi:10.1080/15592294.2017.1389361
590 591	31. Liu C, Marioni RE, Hedman ÅK, et al. A DNA methylation biomarker of alcohol consumption. <i>Mol Psychiatry</i> . 2018;23(2):422-433. doi:10.1038/mp.2016.192
592	32. Elliott HR, Tillin T, McArdle WL, et al. Differences in smoking associated DNA methylation
593	patterns in South Asians and Europeans. <i>Clin Epigenetics</i> . 2014;6(1):4. doi:10.1186/1868-7083-
594	6-4
595	33. Zhang Y, Elgizouli M, Schöttker B, Holleczek B, Nieters A, Brenner H. Smoking-associated DNA
596	methylation markers predict lung cancer incidence. <i>Clin Epigenetics</i> . 2016;8(1):127.
597	doi:10.1186/s13148-016-0292-4
598	34. Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: a robust classifier to
599	determine smoking status from DNA methylation data. <i>Epigenomics</i> . 2019;11(13):1469-1486.
600	doi:10.2217/epi-2019-0206
601 602 603	35. Sadahiro R, Knight B, James F, et al. Major surgery induces acute changes in measured DNA methylation associated with immune response pathways. <i>Sci Rep</i> . 2020;10(1):5743. doi:10.1038/s41598-020-62262-x
604	36. Sehl ME, Rickabaugh TM, Shih R, et al. The Effects of Anti-retroviral Therapy on Epigenetic Age
605	Acceleration Observed in HIV-1-infected Adults. <i>Pathog Immun</i> . 2020;5(1):291.
606	doi:10.20411/pai.v5i1.376
607 608 609	37. Corley MJ, Pang APS, Dody K, et al. Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19. <i>J Leukoc Biol</i> . 2021;110(1):21-26. doi:10.1002/JLB.5HI0720-466R

610	38. Dugué PA, Bassett JK, Wong EM, et al. Biological Aging Measures Based on Blood DNA
611	Methylation and Risk of Cancer: A Prospective Study. JNCI Cancer Spectr. 2021;5(1).
612	doi:10.1093/jncics/pkaa109
613 614 615	39. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. <i>Bioinformatics</i> . 2014;30(10):1363-1369. doi:10.1093/bioinformatics/btu049
616	40. Reinius LE, Acevedo N, Joerink M, et al. Differential DNA Methylation in Purified Human Blood
617	Cells: Implications for Cell Lineage and Studies on Disease Susceptibility. <i>PLoS One</i> .
618	2012;7(7):e41361. doi:10.1371/journal.pone.0041361
619 620 621	41. Salas LA, Koestler DC, Butler RA, et al. An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray. <i>Genome Biol.</i> 2018;19(1):64. doi:10.1186/s13059-018-1448-7
622	42. Levine ME. Modeling the Rate of Senescence: Can Estimated Biological Age Predict Mortality
623	More Accurately Than Chronological Age? <i>J Gerontol A Biol Sci Med Sci</i> . 2013;68(6):667-674.
624	doi:10.1093/gerona/gls233
625	43. Tanaka T, Biancotto A, Moaddel R, et al. Plasma proteomic signature of age in healthy humans.
626	Aging Cell. 2018;17(5):e12799. doi:10.1111/acel.12799
627	44. Macdonald-Dunlop E, Taba N, Klarić L, et al. A catalogue of omics biological ageing clocks
628	reveals substantial commonality and associations with disease risk. <i>Aging</i> . 2022;14(2):623-659.
629	doi:10.18632/aging.203847
630	45. van den Akker EB, Trompet S, Barkey Wolf JJH, et al. Metabolic Age Based on the BBMRI-NL ¹ H-
631	NMR Metabolomics Repository as Biomarker of Age-related Disease. <i>Circ Genom Precis Med</i> .
632	2020;13(5):541-547. doi:10.1161/CIRCGEN.119.002610
633	46. Hertel J, Friedrich N, Wittfeld K, et al. Measuring Biological Age via Metabonomics: The
634	Metabolic Age Score. <i>J Proteome Res</i> . 2016;15(2):400-410. doi:10.1021/acs.jproteome.5b00561
635 636 637	47. Berkelmans GFN, Read SH, Gudbjörnsdottir S, et al. Population median imputation was noninferior to complex approaches for imputing missing values in cardiovascular prediction models in clinical practice. <i>J Clin Epidemiol</i> . 2022;145:70-80. doi:10.1016/j.jclinepi.2022.01.011
638 639	48. Klemera P, Doubal S. A new approach to the concept and computation of biological age. <i>Mech Ageing Dev.</i> 2006;127(3):240-248. doi:10.1016/j.mad.2005.10.004
640	49. Olink Proteomics. <i>Data Normalization and Standardization</i> .; 2021. Accessed January 12, 2023.
641	https://www.olink.com/content/uploads/2021/09/olink-data-normalization-white-paper-
642	v2.0.pdf
643	50. Mathieu Bastian SHMJacomy. Bastian M., Heymann S., Jacomy M. (2009). Gephi: an open
644	source software for exploring and manipulating networks. International AAAI Conference on
645	Weblogs and Social Media.

646	51. Shannon P, Markiel A, Ozier O, et al. Cytoscape: A Software Environment for Integrated Models
647	of Biomolecular Interaction Networks. <i>Genome Res</i> . 2003;13(11):2498-2504.
648	doi:10.1101/gr.1239303
649 650	52. Weidner C, Lin Q, Koch C, et al. Aging of blood can be tracked by DNA methylation changes at just three CpG sites. <i>Genome Biol</i> . 2014;15(2):R24. doi:10.1186/gb-2014-15-2-r24
651	53. Wright EM, Royston P. A Comparison of Statistical Methods for Age-related Reference Intervals.
652	JR Stat Soc Ser A Stat Soc. 1997;160(1):47-69. http://www.jstor.org/stable/2983379
653	54. BURRITT MF, SLOCKBOWER JM, FORSMAN RW, OFFORD KP, BERGSTRALH EJ, SMITHSON WA.
654	Pediatric Reference Intervals for 19 Biologic Variables in Healthy Children. <i>Mayo Clin Proc</i> .
655	1990;65(3):329-336. doi:10.1016/S0025-6196(12)62533-6
656	55. L. Blackburn H, Schroeder B, Turner C, D. Shriver C, L. Ellsworth D, E. Ellsworth R. Management
657	of Incidental Findings in the Era of Next-generation Sequencing. <i>Curr Genomics</i> .
658	2015;16(3):159-174. doi:10.2174/1389202916666150317232930
659 660	56. Rutledge J, Oh H, Wyss-Coray T. Measuring biological age using omics data. <i>Nat Rev Genet</i> . 2022;23(12):715-727. doi:10.1038/s41576-022-00511-7
661 662	57. Karczewski KJ, Snyder MP. Integrative omics for health and disease. <i>Nat Rev Genet.</i> 2018;19(5):299-310. doi:10.1038/nrg.2018.4
663	58. Pusparum M, Ertaylan G, Thas O. From population to subject-specific reference intervals.
664	Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence
665	and Lecture Notes in Bioinformatics). 2020;12140 LNCS:468-482. doi:10.1007/978-3-030-50423-
666	6_35/FIGURES/7
667 668 669	59. Pusparum M, Ertaylan G, Thas O. Individual reference intervals for personalised interpretation of clinical and metabolomics measurements. <i>J Biomed Inform</i> . 2022;131:104111. doi:10.1016/j.jbi.2022.104111
670	